Table of Content

1. Executive Summary


2. Introduction

2.1 Hidradenitis Suppurativa: An Overview
2.1.1 Hidradenitis Suppurativa Overview
2.1.2 The Hurley Staging System in Hidradenitis Suppurativa (HS)


3. Global Market Analysis

3.1 Global Hidradenitis Suppurativa Market: An Analysis

3.1.1 Global Hidradenitis Suppurativa Market: An Overview
3.1.2 Global Hidradenitis Suppurativa Market by Value
3.1.3 Global Hidradenitis Suppurativa Market by Region (The US, Europe, and Rest of the World)

3.2 The US Hidradenitis Suppurativa Market: An Analysis

3.2.1 The US Hidradenitis Suppurativa Market: An Overview
3.2.2 The US Hidradenitis Suppurativa Market by Value

3.3 Europe Hidradenitis Suppurativa Market: An Analysis

3.3.1 Europe Hidradenitis Suppurativa Market: An Overview
3.3.2 Europe Hidradenitis Suppurativa Market by Value
3.3.3 Europe Hidradenitis Suppurativa Market by Region (Germany, UK and Rest of Europe)
3.3.4 Germany Hidradenitis Suppurativa Market by Value
3.3.5 UK Hidradenitis Suppurativa Market by Value
3.3.6 Rest of Europe Hidradenitis Suppurativa Market by Value

3.4 Rest of the World Hidradenitis Suppurativa Market: An Analysis

3.4.1 Rest of the World Hidradenitis Suppurativa Market: An Overview
3.4.2 Rest of the World Hidradenitis Suppurativa Market by Value


4. The US Market Analysis

4.1 The US Hidradenitis Suppurativa Market: Patient Analysis

4.1.1 The US Hidradenitis Suppurativa Market: Patients Overview
4.1.2 The US Stage II Hidradenitis Suppurativa Market by Patients
4.1.3 The US Stage III Hidradenitis Suppurativa Market by Patients
4.1.4 The US Hidradenitis Suppurativa Market by Treated Patients

4.2 The US Povorcitinib Hidradenitis Suppurativa Market: An Analysis

4.2.1 The US Povorcitinib Hidradenitis Suppurativa Market: An Overview
4.2.2 The US Povorcitinib Hidradenitis Suppurativa Market by Treated Patients
4.2.3 The US Povorcitinib Hidradenitis Suppurativa Market by Value

4.3 The US Bimekizumab Hidradenitis Suppurativa Market: An Analysis

4.3.1 The US Bimekizumab Hidradenitis Suppurativa Market: An Overview
4.3.2 The US Bimekizumab Hidradenitis Suppurativa Market by Treated Patients
4.3.3 The US Bimekizumab Hidradenitis Suppurativa Market by Value

4.4 The US Sonelokimab Hidradenitis Suppurativa Market: An Analysis

4.4.1 The US Sonelokimab Hidradenitis Suppurativa Market: An Overview
4.4.2 The US Sonelokimab Hidradenitis Suppurativa Market by Treated Patients
4.4.3 The US Sonelokimab Hidradenitis Suppurativa Market by Value


5. Impact of COVID-19

5.1 Impact of COVID-19

5.1.1 Impact of COVID-19 on Hidradenitis Suppurativa Market
5.1.2 Post COVID-19 Impact


6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increased Disposable Income
6.1.2 Rising Cases of Obesity
6.1.3 Rapid Urbanization
6.1.4 Increase in Smoking Rates
6.1.5 Rise in The Incidence Of Skin Diseases
6.1.6 Rising Prevalence of Hidradenitis Suppurativa

6.2 Challenges
6.2.1 High Cost
6.2.2 Unmet Medical Needs and Drug Resistance
6.2.3 Delays in Treatment Completion

6.3 Market Trends
6.3.1 Use of Artificial Intelligence (AI) in Vaccine and Drug Design
6.3.2 Technological Advancements
6.3.3 Surging Drug Approvals and Launches


7. Competitive Landscape

7.1 Global Hidradenitis Suppurativa Market Players: Current HS Pipeline Comparison
7.2 Global HS Market Players: HS Trial Design and Patient Population Comparison


8. Company Profiles

8.1 Pfizer Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategies

8.2 Eli Lilly and Company
8.2.1 Business Overview
8.2.2 Revenue by Products
8.2.3 Business Strategy

8.3 AbbVie Inc.
8.3.1 Business Overview
8.3.2 Operating Regions
8.3.3 Business Strategy

8.4 UCB S.A.
8.4.1 Business Overview
8.4.2 Net Sales by Products
8.4.3 Business Strategy

8.5 Incyte Corporation
8.5.1 Business Overview
8.5.2 Revenue by Products
8.5.3 Business Strategy

8.6 Novartis AG
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy

8.7 Boehringer Ingelheim
8.7.1 Business Overview
8.7.2 Operating Business
8.7.3 Business Strategy

8.8 Aclaris Therapeutics, Inc.
8.8.1 Business Overview
8.8.2 Operating Segments
8.8.3 Business Strategy

8.9 InflaRx N.V.
8.9.1 Business Overview
8.9.2 Business Strategy

8.10 Moonlake Immunotherapeutics
8.10.1 Business Overview
8.10.2 Business Strategy

8.11 Acelyrin, Inc.
8.11.1 Business Overview
8.11.2 Business Strategy

8.12 Kymera Therapeutics, Inc.
8.12.1 Business Overview
8.12.2 Business Strategy

List of Figures

Figure 1: The Hurley Staging System in Hidradenitis Suppurativa (HS)
Figure 2: Global Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Billion)
Figure 3: Global Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Billion)
Figure 4: Global Hidradenitis Suppurativa Market by Region; 2022 (Percentage, %)
Figure 5: The US Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 6: The US Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Billion)
Figure 7: Europe Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 8: Europe Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Million)
Figure 9: Europe Hidradenitis Suppurativa Market by Region; 2022 (Percentage, %)
Figure 10: Germany Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 11: Germany Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Million)
Figure 12: UK Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 13: UK Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Million)
Figure 14: Rest of Europe Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 15: Rest of Europe Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Million)
Figure 16: Rest of the World Hidradenitis Suppurativa Market by Value; 2018-2022 (US$ Million)
Figure 17: Rest of the World Hidradenitis Suppurativa Market by Value; 2023-2030 (US$ Million)
Figure 18: The US Stage II Hidradenitis Suppurativa Market by Patients; 2022-2030 (Thousand, Percentage, %)
Figure 19: The US Stage III Hidradenitis Suppurativa Market by Patients; 2022-2030 (Thousand, Percentage, %)
Figure 20: The US Hidradenitis Suppurativa Market by Treated Patients; 2022-2030 (Thousand)
Figure 21: The US Povorcitinib Hidradenitis Suppurativa Market by Treated Patients; 2027-2030 (Number)
Figure 22: The US Povorcitinib Hidradenitis Suppurativa Market by Value; 2027-2030 (US$ Million)
Figure 23: The US Bimekizumab Hidradenitis Suppurativa Market by Treated Patients; 2024-2030 (Number)
Figure 24: The US Bimekizumab Hidradenitis Suppurativa Market by Value; 2024-2030 (US$ Million)
Figure 25: The US Sonelokimab Hidradenitis Suppurativa Market by Treated Patients; 2027-2030 (Number)
Figure 26: The US Sonelokimab Hidradenitis Suppurativa Market by Value; 2027-2030 (US$ Million)
Figure 27: Global GNI per Capita; 2016-2021 (US$ Million)
Figure 28: Global Numbers Of People With Obesity And Severe Obesity, 2010-2030 (Million)
Figure 29: Global Urban Population; 2016, 2021 & 2050 (Billion)
Figure 30: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US $Billion)
Figure 31: Pfizer Inc. Revenues by Operating Segments; 2022 (Percentage, %)
Figure 32: Eli Lilly and Company Revenue by Products; 2022 (Percentage, %)
Figure 33: AbbVie Inc. Net revenue by regions; 2022 (Percentage, %)
Figure 34: UCB S.A. Net Sales by Products; 2022 (Percentage, %)
Figure 35: Incyte Corporation Revenue by Products; 2021 (Percentage, %)
Figure 36: Novartis AG Net Sales by Segments; 2022 (Percentage, %)
Figure 37: Boehringer Ingelheim Net Sales by Business; 2021 (Percentage, %)
Figure 38: Aclaris Therapeutics, Inc. Revenue by Segments; 2022 (Percentage, %)
Table 1: Global Hidradenitis Suppurativa Market Players: Current HS Pipeline Comparison
Table 2: Global HS Market Players: HS Trial Design and Patient Population Comparison